The North America pharmacogenomics market size was valued at USD 4.10 billion in 2025 and is projected to grow from USD 4.62 billion in 2026 to reach USD 11.93 billion by 2034, growing at a CAGR of 12.6% during the forecast period 2026–2034.
In pharmacogenomics, genes are studied concerning drug response. This field combines pharmacology (the science of pharmaceuticals) and genomics (the study of genes and their functions) to create effective, safe treatments depending on a person's genetic composition.
Many medications on the market today are "one size fits all", but they don't work the same for everyone. It's difficult to tell who will benefit from a drug and who will have side effects (called adverse drug reactions). Adverse medication reactions cause a considerable number of hospitalisations and deaths.
Researchers are trying to figure out how genetic variations affect the body's response to drugs. These genetic distinctions will be utilized to forecast whether a treatment will be successful for a specific person and which dosage will help avoid unpleasant drug reactions. Conditions like clopidogrel resistance, warfarin sensitivity, warfarin resistance, malignant hyperthermia, Stevens-Johnson syndrome/toxic epidermal necrolysis, and thiopurine S-methyltransferase deficiency can change how a person responds to certain medicines.
The science of pharmacogenomics is expanding, and clinical studies are testing new approaches. Pharmacogenomics will be utilized in the future to develop personalized medications to treat a variety of diseases, including cardiovascular disease, Alzheimer's disease, cancer, and asthma.
Download a Free Sample To learn more about this report,
AI-Assisted Genotype-to-Phenotype Interpretation
The North America Pharmacogenomics Market analysis shows that AI-assisted interpretation is becoming more relevant as laboratories and healthcare providers handle larger volumes of genetic variants and drug-response information. The transition toward automated genotype-to-phenotype interpretation supports faster translation of genetic results into clinically meaningful metabolizer categories and treatment recommendations, while a 2025 University of Florida implementation study described structured genomic data and clinical decision-support tools within its Epic Genomics module. This shift supports faster interpretation of complex pharmacogenomic results and wider use of precision prescribing.
Pharmacogenomics Integration with Electronic Health Records
The North America Pharmacogenomics Market analysis shows that integration with electronic health records is becoming more important as providers seek to use genetic results directly during prescribing decisions. The transition toward structured PGx data and electronic clinical decision support allows test results to remain accessible and trigger drug-specific recommendations, with a 2025 UCSF program covering 56 medications and 15 genes and incorporating 233 prescribing alerts into its EHR. This integration supports point-of-care pharmacogenomic decision-making and strengthens the use of PGx testing in routine clinical workflows.
Pharmacogenomic Testing in Cardiovascular Care and Clinical Research on Drug-Gene Associations Drive Market
Genetic variation in drug metabolism and response can affect how patients respond to medicines used for cardiovascular conditions, creating a role for pharmacogenomic testing in treatment decisions.Genotype information can help clinicians assess medication response for therapies such as clopidogrel, where CYP2C19 variants can influence antiplatelet activity.Hospitals, cardiology centers, and clinical laboratories therefore require pharmacogenomic tests that provide relevant genotype information for medication selection.For example, CYP2C19 testing can identify patients with reduced clopidogrel metabolism and support consideration of alternative antiplatelet therapy.Broader clinical use of genotype-guided cardiovascular care supports test utilization and strengthens the need for pharmacogenomic laboratory services.
Clinical research on drug-gene relationships generates evidence about how genetic variants affect medication efficacy, metabolism, and adverse reactions.Validated drug-gene evidence supports the development of clinical guidelines, testing panels, and laboratory services for genotype-guided treatment.Pharmaceutical companies, research institutions, and diagnostic laboratories therefore require pharmacogenomic testing platforms and sequencing or genotyping services during clinical studies.For example, research on CYP2C19 and clopidogrel has helped establish a clinically relevant connection between genotype and antiplatelet response.A broader evidence base for drug-gene associations supports clinical adoption and creates additional opportunities for pharmacogenomic testing providers.
Shortage of Skilled Pharmacogenomics Professionals and Long Turnaround Times for Certain Genetic Tests Restrain Market Expansion
A shortage of skilled pharmacogenomics professionals limits the capacity to interpret genetic variants and translate results into treatment decisions.Limited expertise can create delays in test interpretation and increase the workload for healthcare providers and laboratories. This workforce gap can restrict clinical adoption and slow the integration of pharmacogenomics into routine care.
Long turnaround times for certain genetic tests can delay the availability of pharmacogenomic results during treatment decisions.Extended laboratory processing and reporting periods can reduce the usefulness of testing when clinicians need timely guidance for medication selection or dosing.These delays can limit physician adoption and reduce the use of pharmacogenomic testing in time-sensitive clinical settings.
Pharmacogenomic Testing for Oncology Treatment Selection and Direct-to-Consumer Pharmacogenomic Testing Services Offers Growth Opportunities
Oncology centers, hospitals, diagnostic laboratories, pharmaceutical companies, and pharmacogenomic providers are key beneficiaries, as testing can help identify genetic differences that affect responses to certain cancer medicines. Specialized testing creates revenue through genomic panels, laboratory services, clinical interpretation, and partnerships with cancer-care providers. Companies such as Foundation Medicine and Tempus offer genomic testing solutions used in oncology.
Genetic testing companies, telehealth providers, pharmacies, and consumers are key beneficiaries, as direct access can expand pharmacogenomic testing beyond traditional clinical settings. DTC services create revenue through test kits, laboratory analysis, interpretation reports, and follow-up consultations. Companies such as 23andMe and Myriad Genetics offer consumer or patient-focused genetic testing services, supporting market growth.
EHR Integration and Interoperability Gaps and Variation in Testing Platforms and Result Interpretation Hinders Growth
Pharmacogenomic results must connect with EHRs and clinical decision-support systems to become useful at the point of care. Differences in EHR architecture and limited interoperability increase integration work for testing companies and healthcare providers, slowing broader adoption
Differences in test panels, variant coverage, reporting formats, and interpretation approaches can make results harder to compare across laboratories. This complexity increases workflow requirements and can discourage providers from adopting testing across multiple clinical settings.
Instruments include laboratory systems and equipment used to perform genetic analysis and pharmacogenomic testing. Software & Services support genetic data analysis, genotype interpretation, clinical reporting, testing workflows, and related laboratory services.
Request Customizationto receive a tailored report.
Polymerase Chain Reaction is used for targeted genetic analysis and detection of specific variants relevant to drug response. DNA Sequencing enables detailed analysis of genetic variants and supports broader pharmacogenomic testing applications.Microarray technology allows simultaneous analysis of multiple genetic markers associated with medication response and treatment decisions.Mass Spectrometry supports accurate molecular analysis and can be used in pharmacogenomic workflows requiring precise analytical measurements. Electrophoresis separates and analyzes nucleic acid fragments and supports selected genetic testing procedures. Others include additional molecular and analytical technologies used for identifying genetic variants and supporting pharmacogenomic analysis.
Drug Discovery & Development uses pharmacogenomic information to study drug response, identify patient subgroups, and support development of targeted therapies. Oncology applications use genetic information to guide treatment selection and help identify therapies suited to specific tumor-related biomarkers.Neurology applications support the assessment of genetic factors that can influence responses to medications used for neurological conditions.Cardiology applications use drug-gene information to support medication selection and dosing for cardiovascular therapies.Pain Management uses pharmacogenomic testing to assess genetic differences that may influence responses to selected pain medications. Others include psychiatric, infectious disease, and other therapeutic applications where genetic information can support medication-related decisions.
Speak to an Analystto discuss market opportunities.
The North America Pharmacogenomics Market accounted for the largest regional share of 42.35% in 2025. The region benefits from advanced healthcare infrastructure, established genomic testing capabilities, and strong adoption of personalized medicine. Growing use of pharmacogenomic testing to guide drug selection and dosing further supports market growth.
The NIH’s All of Us Research Program is designed to build a genomic and health-data resource of more than 1 million U.S. participants, with the resulting data expected to advance pharmacogenomics and improve treatment selection, supporting future demand for pharmacogenomic testing.Genome Canada’s Canadian Precision Health Initiative is building a national dataset of more than 100,000 genomes over four years, with the initiative specifically targeting improved drug safety and effectiveness through genomic data, supporting future adoption of pharmacogenomic testing.
The North America Pharmacogenomics Market is moderately fragmented, with the market ecosystem comprising pharmaceutical companies, genetic testing laboratories, diagnostic companies, biotechnology firms, hospitals, research institutions, and specialized precision-medicine providers.The leading players in the North America Pharmacogenomics Market include Admera Health, Abbott Laboratories, Agilent Technologies, Novartis AG, and Dynamic DNA Laboratories; Admera Health offers the PGxOne™ Plus pharmacogenomic test covering 16 genes and 99 drug-response conditions, Abbott reported USD 44.3 billion in 2025 revenue and provides diagnostic systems and tests, Agilent generated USD 6.95 billion in fiscal 2025 revenue across life sciences and diagnostics, Novartis reported USD 54.53 billion in 2025 net sales and develops medicines supported by genomic and precision-medicine approaches, while Dynamic DNA Laboratories offers multiple PGx panels, including a 125-condition, 18-gene Comprehensive PGx Panel; however, a verified cumulative North America pharmacogenomics market share for these five companies is not publicly disclosed through company filings or other non-market-research sources, so assigning a defensible cumulative percentage would require estimation as market share.
Established players compete mainly through test accuracy, clinical validation, broad pharmacogenomic panels, laboratory infrastructure, regulatory compliance, data interpretation capabilities, healthcare-provider networks, and integration with clinical workflows, while the market ecosystem includes emerging and regional players that compete through specialized gene-drug panels, faster testing, personalized reporting, targeted clinical applications, flexible testing models, and cost-efficient services. The presence of numerous U.S. laboratories offering pharmacogenomic tests, including comprehensive panels and targeted drug-response testing, supports a diverse competitive environment.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Red Biotechnology Market Size, Share, Growth, Forecast, 2034
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Cell Line Development Services Market Size, Share, 2034
Base Editing Market Size, Share, Growth, Analysis, Report, 2034
Metagenomic Sequencing Market Size, Share, Growth, Analysis, 2034
Gene Therapy Cell Culture Media Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com